Abstract
Therapeutic resistance of acute myeloid leukemia stem cells, enriched in the CD34+38−123+ progenitor population, is supported by extrinsic factors such as the bone marrow niche. Here, we report that when adherent onto fibronectin or osteoblast components, CD34+38−123+ progenitors survive through an integrin-dependent activation of glycogen synthase kinase 3β (GSK3β) by serine 9-dephosphorylation. Strikingly, GSK3β-mediated survival was restricted to leukemic progenitors from female patients. GSK3β inhibition restored sensitivity to etoposide, and impaired the clonogenic capacities of adherent leukemic progenitors from female patients. In leukemic progenitors from female but not male patients, the scaffolding protein RACK1, activated downstream of α5β1-integrin engagement, was specifically upregulated and controlled GSK3β activation through the phosphatase protein phosphatase 2A (PP2A). In a mirrored manner, survival of adherent progenitors (CD34+38−) from male but not female healthy donors was partially dependent on this pathway. We conclude that the GSK3β-dependent survival pathway might be sex-specific in normal immature population and flip-flopped upon leukemogenesis. Taken together, our results strengthen GSK3β as a promising target for leukemic stem cell therapy and reveal gender differences as a new parameter in anti-leukemia therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Berghöfer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H . (2006). TLR7 ligands induce higher IFN-alpha production in females. J Immunol 177: 2088–2096.
Bhatia R, McCarthy JB, Verfaillie CM . (1996). Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 87: 3883–3891.
Del Vecchio I, Zuccotti A, Pisano F, Canneva F, Lenzken SC, Rousset F et al. (2009). Functional mapping of the promoter region of the GNB2L1 human gene coding for RACK1 scaffold protein. Gene 430: 17–29.
De Toni F, Racaud-Sultan C, Chicanne G, Mas VM, Cariven C, Mesange F et al. (2006). A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 25: 3113–3122.
De Toni-Costes F, Despeaux M, Bertrand J, Bourogaa E, Ysebaert L, Payrastre B et al. (2010). A new α5β1 integrin-dependent survival pathway through GSK3β activation in leukemic cells. PloS ONE 5: e9807.
De Vries JF, Falkenburg JH, Willemze R, Barge RM . (2006). The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells. Haematologica 91: 912–919.
Despeaux M, Labat E, Gadelorge M, Prade N, Bertrand J, Demur C et al. (2011). Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells. Leukemia (advance online publication 7 June 2011; doi:10.1038/leu.2011.145).
Dick JE, Lapidot T . (2005). Biology of normal and acute myeloid leukemia stem cells. Int J Hematol 82: 389–396.
Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY et al. (2007). Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 27: 4006–4017.
Du L, Bayir H, Lai Y, Zhang X, Kochanek PM, Watkins SC et al. (2004). Innate gender-based proclivity in response to cytotoxicity and programmed cell death pathway. J Biol Chem 279: 38563–38570.
Edderkaoui M, Hong P, Lee JK, Pandol SJ, Gukovskaya AS . (2007. Insulin-like growth factor-I receptor mediates the prosurvival effect of fibronectin. J Biol Chem 282: 26646–26655.
Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS et al. (2005). The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105: 4163–4169.
Holmes T, O'Brien TA, Knight R, Lindeman R, Shen S, Song E et al. (2008). Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. Stem Cells 26: 1288–1297.
Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S et al. (2007). Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25: 1315–1321.
Ivaska J, Nissinen L, Immonen N, Eriksson JE, Kähäri VM, Heino J . (2002). Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta. Mol Cell Biol 22: 1352–1359.
Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE . (2006). Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12: 1167–1174.
Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L et al. (2009). Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5: 31–42.
Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL et al. (2000). The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14: 1777–1784.
Kiely PA, Baillie GS, Lynch MJ, Houslay MD, O'Connor R . (2008). Tyrosine 302 in RACK1 is essential for insulin-like growth factor-I-mediated competitive binding of PP2A and beta1 integrin and for tumor cell proliferation and migration. J Biol Chem 283: 22952–22961.
Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M et al. (2009). Functional proteomic profiling of AML predicts response and survival. Blood 113: 154–164.
Kubota T, Yokosawa N, Yokota S, Fujii N . (2002). Association of mumps virus V protein with RACK1 results in dissociation of STAT-1 from the alpha interferon receptor complex. J Virol 76: 12676–12682.
Li ZW, Dalton WS . (2006). Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 20: 333–342.
Luo J . (2009). Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 273: 194–200.
Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A et al. (2003). Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9: 1158–1165.
Mayack SR, Shadrach JL, Kim FS, Wagers AJ . (2010). Systemic signals regulate ageing and rejuvenation of blood stem cell niches. Nature 463: 495–500.
Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD . (2007). Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 110: 735–742.
Papasozomenos SCh, Shanavas A . (2002). Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer's disease. Proc Natl Acad Sci USA 99: 1140–1145.
Recher C, Ysebaert L, Beyne-Rauzy O, Mansat-De Mas V, Ruidavets JB, Cariven P et al. (2004). Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res 64: 3191–3197.
Sampaio AL, Zahn G, Leoni G, Vossmeyer D, Christner C, Marshall JF et al. (2010). Inflammation-dependent \{alpha\}5\{beta\}1 (very late antigen-5) expression on leukocytes reveals a functional role for this. J Leukoc Biol 87: 877–884.
Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A et al. (2010). Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 28: 275–280.
Schiller G, Gajewski J, Lee M, Ho W, Territo M, Champlin R . (1994). Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Leuk Lymphoma 15: 85–90.
Sun M, Song L, Li Y, Zhou T, Jope RS . (2008). Identification of an antiapoptotic protein complex at death receptors. Cell Death Differ 15: 1887–1900.
Trowbridge JJ, Xenocostas A, Moon RT, Bhatia M . (2006). Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med 12: 89–98.
Vialle-Castellano A, Gaugler B, Mohty M, Isnardon D, van Baren N, Olive D . (2004). Abundant expression of fibronectin is a major feature of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia 18: 426–433.
Wang Z, Iwasaki M, Ficara F, Lin C, Matheny C, Wong SH et al. (2010). GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 17: 597–608.
Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML . (2008). Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 455: 1205–1209.
Xu Q, Thompson JE, Carroll M . (2005). mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 106: 4261–4268.
Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N, Ruidavets JB et al. (2006). Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 20: 1211–1216.
Acknowledgements
We thank Dr Jean-Emmanuel Sarry for critical reading of the manuscript and the ‘plateforme de cytométrie’ of IFR150. Association de Recherche contre le Cancer (Contract Nos. 3638 and 8407), Institut National du Cancer (Contract no. 07/3D1616/IABC-23-8/NC-NG), DGRSRT/INSERM cooperation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Bertrand, J., Despeaux, M., Joly, S. et al. Sex differences in the GSK3β-mediated survival of adherent leukemic progenitors. Oncogene 31, 694–705 (2012). https://doi.org/10.1038/onc.2011.258
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.258
Keywords
This article is cited by
-
Sexual dimorphism in PAR2-dependent regulation of primitive colonic cells
Biology of Sex Differences (2019)
-
RACK1 promotes the proliferation of THP1 acute myeloid leukemia cells
Molecular and Cellular Biochemistry (2013)